NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,338.18 -141.19 (-0.76%) CRUDE OIL
77.94 -0.44 (-0.56%) GOLD FUTURES
2,325.30 +1.10 (+0.05%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
49,898.57 -999.50 (-1.96%)
AZN May 2024 67.000 call
| Previous close | 4.3800 |
| Open | 4.3800 |
| Bid | 7.6000 |
| Ask | 10.9500 |
| Strike | 67.00 |
| Expiry date | 2024-05-03 |
| Day's range | 4.3800 - 4.3800 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
- Reuters
PRESS DIGEST-British Business - May 8
The following are the top stories on the business pages of British newspapers. - Social media apps including TikTok and Instagram will be told to "tame aggressive algorithms" pushing harmful content to children, under new rules as a part of a plan from UK's communications regulator Ofcom. - BP CEO Murray Auchincloss said that switching the energy giant's listing from London to New York is "not on the agenda", despite the FTSE 100 group's valuation trailing that of American peers.
The GuardianAstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines
Pharmaceutical company says newer shots led to decline in demand for AstraZeneca vaccine, which is no longer being manufactured or supplied
- Reuters
UPDATE 2-AstraZeneca says it will withdraw COVID-19 vaccine globally as demand dips
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic. The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.
